Antibody-mediated protection against MERS-CoV in the murine model.
Identifieur interne : 000508 ( PubMed/Curation ); précédent : 000507; suivant : 000509Antibody-mediated protection against MERS-CoV in the murine model.
Auteurs : R R C. New [Royaume-Uni] ; B D Moore [Royaume-Uni] ; W. Butcher [Royaume-Uni] ; R. Mahood [Royaume-Uni] ; M S Lever [Royaume-Uni] ; S. Smither [Royaume-Uni] ; L. O'Brien [Royaume-Uni] ; S A Weller [Royaume-Uni] ; M. Bayliss [Royaume-Uni] ; L C D. Gibson [Royaume-Uni] ; C. Macleod [Royaume-Uni] ; M. Bogus [Royaume-Uni] ; R. Harvey [Royaume-Uni] ; N. Almond [Royaume-Uni] ; E D Williamson [Royaume-Uni]Source :
- Vaccine [ 1873-2518 ] ; 2019.
Abstract
Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.
DOI: 10.1016/j.vaccine.2019.05.074
PubMed: 31178378
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000508
Links to Exploration step
pubmed:31178378Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibody-mediated protection against MERS-CoV in the murine model.</title>
<author><name sortKey="New, R R C" sort="New, R R C" uniqKey="New R" first="R R C" last="New">R R C. New</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, B D" sort="Moore, B D" uniqKey="Moore B" first="B D" last="Moore">B D Moore</name>
<affiliation wicri:level="1"><nlm:affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Pure & Applied Chemistry, University of Strathclyde, Glasgow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Butcher, W" sort="Butcher, W" uniqKey="Butcher W" first="W" last="Butcher">W. Butcher</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mahood, R" sort="Mahood, R" uniqKey="Mahood R" first="R" last="Mahood">R. Mahood</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lever, M S" sort="Lever, M S" uniqKey="Lever M" first="M S" last="Lever">M S Lever</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Smither, S" sort="Smither, S" uniqKey="Smither S" first="S" last="Smither">S. Smither</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="O Brien, L" sort="O Brien, L" uniqKey="O Brien L" first="L" last="O'Brien">L. O'Brien</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Weller, S A" sort="Weller, S A" uniqKey="Weller S" first="S A" last="Weller">S A Weller</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bayliss, M" sort="Bayliss, M" uniqKey="Bayliss M" first="M" last="Bayliss">M. Bayliss</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gibson, L C D" sort="Gibson, L C D" uniqKey="Gibson L" first="L C D" last="Gibson">L C D. Gibson</name>
<affiliation wicri:level="1"><nlm:affiliation>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Macleod, C" sort="Macleod, C" uniqKey="Macleod C" first="C" last="Macleod">C. Macleod</name>
<affiliation wicri:level="1"><nlm:affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Pure & Applied Chemistry, University of Strathclyde, Glasgow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bogus, M" sort="Bogus, M" uniqKey="Bogus M" first="M" last="Bogus">M. Bogus</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Harvey, R" sort="Harvey, R" uniqKey="Harvey R" first="R" last="Harvey">R. Harvey</name>
<affiliation wicri:level="1"><nlm:affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Institute for Biological Standards and Control, Potters Bar</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Almond, N" sort="Almond, N" uniqKey="Almond N" first="N" last="Almond">N. Almond</name>
<affiliation wicri:level="1"><nlm:affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Institute for Biological Standards and Control, Potters Bar</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Williamson, E D" sort="Williamson, E D" uniqKey="Williamson E" first="E D" last="Williamson">E D Williamson</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK. Electronic address: dewilliamson@dstl.gov.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31178378</idno>
<idno type="pmid">31178378</idno>
<idno type="doi">10.1016/j.vaccine.2019.05.074</idno>
<idno type="wicri:Area/PubMed/Corpus">000508</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000508</idno>
<idno type="wicri:Area/PubMed/Curation">000508</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000508</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antibody-mediated protection against MERS-CoV in the murine model.</title>
<author><name sortKey="New, R R C" sort="New, R R C" uniqKey="New R" first="R R C" last="New">R R C. New</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, B D" sort="Moore, B D" uniqKey="Moore B" first="B D" last="Moore">B D Moore</name>
<affiliation wicri:level="1"><nlm:affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Pure & Applied Chemistry, University of Strathclyde, Glasgow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Butcher, W" sort="Butcher, W" uniqKey="Butcher W" first="W" last="Butcher">W. Butcher</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mahood, R" sort="Mahood, R" uniqKey="Mahood R" first="R" last="Mahood">R. Mahood</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lever, M S" sort="Lever, M S" uniqKey="Lever M" first="M S" last="Lever">M S Lever</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Smither, S" sort="Smither, S" uniqKey="Smither S" first="S" last="Smither">S. Smither</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="O Brien, L" sort="O Brien, L" uniqKey="O Brien L" first="L" last="O'Brien">L. O'Brien</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Weller, S A" sort="Weller, S A" uniqKey="Weller S" first="S A" last="Weller">S A Weller</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bayliss, M" sort="Bayliss, M" uniqKey="Bayliss M" first="M" last="Bayliss">M. Bayliss</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gibson, L C D" sort="Gibson, L C D" uniqKey="Gibson L" first="L C D" last="Gibson">L C D. Gibson</name>
<affiliation wicri:level="1"><nlm:affiliation>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Macleod, C" sort="Macleod, C" uniqKey="Macleod C" first="C" last="Macleod">C. Macleod</name>
<affiliation wicri:level="1"><nlm:affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Pure & Applied Chemistry, University of Strathclyde, Glasgow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bogus, M" sort="Bogus, M" uniqKey="Bogus M" first="M" last="Bogus">M. Bogus</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Harvey, R" sort="Harvey, R" uniqKey="Harvey R" first="R" last="Harvey">R. Harvey</name>
<affiliation wicri:level="1"><nlm:affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Institute for Biological Standards and Control, Potters Bar</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Almond, N" sort="Almond, N" uniqKey="Almond N" first="N" last="Almond">N. Almond</name>
<affiliation wicri:level="1"><nlm:affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Institute for Biological Standards and Control, Potters Bar</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Williamson, E D" sort="Williamson, E D" uniqKey="Williamson E" first="E D" last="Williamson">E D Williamson</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK. Electronic address: dewilliamson@dstl.gov.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Defence Science & Technology Laboratory, Porton Down, Salisbury</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">31178378</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>37</Volume>
<Issue>30</Issue>
<PubDate><Year>2019</Year>
<Month>Jul</Month>
<Day>09</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Antibody-mediated protection against MERS-CoV in the murine model.</ArticleTitle>
<Pagination><MedlinePgn>4094-4102</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(19)30711-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2019.05.074</ELocationID>
<Abstract><AbstractText>Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.</AbstractText>
<CopyrightInformation>Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>New</LastName>
<ForeName>R R C</ForeName>
<Initials>RRC</Initials>
<AffiliationInfo><Affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK; Faculty of Science and Technology, Middlesex University, The Burroughs, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moore</LastName>
<ForeName>B D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo><Affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Butcher</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mahood</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lever</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smither</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>O'Brien</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weller</LastName>
<ForeName>S A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bayliss</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gibson</LastName>
<ForeName>L C D</ForeName>
<Initials>LCD</Initials>
<AffiliationInfo><Affiliation>Scottish Biomedical Drug Discovery, West of Scotland Science Park, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Macleod</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bogus</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Vaxcine (UK) Ltd, c/o London Bioscience Innovation Centre, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Harvey</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Almond</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>National Institute for Biological Standards and Control, Potters Bar, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Williamson</LastName>
<ForeName>E D</ForeName>
<Initials>ED</Initials>
<AffiliationInfo><Affiliation>Defence Science & Technology Laboratory, Porton Down, Salisbury, UK. Electronic address: dewilliamson@dstl.gov.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>06</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">MERS</Keyword>
<Keyword MajorTopicYN="N">Mucosal immunity</Keyword>
<Keyword MajorTopicYN="N">Neutralising antibody</Keyword>
<Keyword MajorTopicYN="N">Novel vaccine formulation</Keyword>
<Keyword MajorTopicYN="N">Respiratory infection</Keyword>
<Keyword MajorTopicYN="N">Systemic immunity</Keyword>
<Keyword MajorTopicYN="N">Vaccination</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>12</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2019</Year>
<Month>03</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>05</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>6</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>6</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>6</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31178378</ArticleId>
<ArticleId IdType="pii">S0264-410X(19)30711-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2019.05.074</ArticleId>
<ArticleId IdType="pmc">PMC7115393</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Apr;20(4):560-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24655427</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EMBO Mol Med. 2012 Oct;4(10):1015-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22837174</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2016 Sep;133:165-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27468951</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2017 Jun 27;35(30):3780-3788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28579232</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2018 Aug 16;36(34):5210-5217</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30017148</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Rev. 2016 Jul;272(1):80-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27319344</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):81-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26678874</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Aug;22(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27439020</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2010 May;86(2):180-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20153776</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virol J. 2016 Jun 03;13:87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27255185</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2017 Apr;140:55-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28040513</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Res. 2013 Sep;23(9):1069-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23938293</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Crit Rev Biotechnol. 2015 Jun;35(2):235-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24156398</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Mol Immunol. 2010 Sep;7(5):381-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20543857</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2016 Dec 16;91(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27795425</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunology. 2015 Aug;145(4):476-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25762305</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2010 Mar 15;184(6):2756-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20164423</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2017 Jul 3;13(7):1615-1624</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28277821</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Oct;87(19):10777-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23903833</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2012 Nov 20;3(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2014 Jan;52(1):67-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24153118</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2012 Oct 04;17(40):20290</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23078800</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EBioMedicine. 2015 Aug 18;2(10):1438-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26629538</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pathog Glob Health. 2015;109(8):354-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26924345</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Jul;82(14):6927-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18480438</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 Jul 16;32(33):4234-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24120484</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2016 Nov 22;7:13473</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27874853</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):77-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26678878</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000508 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000508 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:31178378 |texte= Antibody-mediated protection against MERS-CoV in the murine model. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:31178378" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |